OYST News and Press, Oyster Point Pharma Inc. From 09/07/22

PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ph...

Summary Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP (“the Fund”) returned -25.9% net in the first ...

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the...

Oyster Point Pharma ( NASDAQ: OYST ) on Wednesday said its nasal spray Tyrvaya for the treatment of dry eye disease would now be covered by the largest Medicare pharmacy benefit manager (PBM) in the U.S. OYST did not name the PBM in its statement . Tyrvaya would be...

PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class phar...

PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class phar...

Oyster Point Pharma, Inc. (OYST) Q2 2022 Results Conference Call August 11, 2022 04:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chi...

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q2 2022 Earnings Call Transcript...

TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2 ’ 22 Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals ...

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-clas...